QQQ0.47%

Trending

MRK0.39%

Feed

News

Sentiment

Info

Historical Prices

home CoinsVITAFOXO

Updated 07:43 AM UTC

VITAFOXOVitaFOXO

$0.013

$0.0₅8490

(0.07%)

Today

Vol3.23

News

all

press releases

No VITAFOXO.X news at the moment.

...

Bullish/Bearish Forum Sentiment

Indicates whether most users posting on a crypto’s stream over the last 24 hours are bearish or bullish.

100

Extremely

Bearish

Neutral

Bullish

Extremely

Bearish

Bullish

N/A

Last score

N/A

1 day ago

1 week ago

1 month ago

3 months ago

6 months ago

1 year ago

Message Board Activity

Measures the total amount of chatter on a stream over the last 24 hours.

100

Extremely

Low

Normal

High

Extremely

Low

High

N/A

Last score

N/A

1 day ago

1 week ago

1 month ago

3 months ago

6 months ago

1 year ago

Discussion Diversity

Measures the number of unique accounts posting on a stream relative to the number of total messages on that stream.

100

Extremely

Low

Normal

High

Extremely

Low

High

N/A

Last score

N/A

1 day ago

1 week ago

1 month ago

3 months ago

6 months ago

1 year ago

AboutThis project will design a new RNA therapeutic that nudges the longevity-linked FOXO3 gene into its health-promoting form to halt the tissue breakdown behind degenerative disc disease—opening a precise, scalable route to drugs that extend healthspan. Dr. Lorna Harries’ lab has identified an innovative way to modulate FOXO3, a well known and yet undrugged longevity target, and propose leveraging it to address chronic lower back pain stemming from degenerative disc disease. They plan to make short, lab-made modified RNA molecules (antisense oligonucleotides) that selectively switch FOXO3’s “good” message on, first in human cells and mini-disc models. Success would yield 1) a lead drug candidate, 2) proof it can restore disc health, and 3) the data needed for patenting and further development. The same molecules could later be adapted to treat many other age-related conditions, helping people stay healthy for longer.

Details

Fundamentals

Mkt Cap

$0.00

24H Volume

$3.23

7D High

$0.0135

FDV

$130,484.00

Circ Supply

0.00

Total Supply

10M

Max Supply

10M

24H High

$0.0131

24H Low

$0.013

Neutral Sentiment

How do you feel about VITAFOXO?

Advertisement|Remove ads.

Latest VITAFOXO News

View

Top Discussions

SPY

What do you think the S&P 500's ($SPY) return will be next week?

13K votes

Sweetgreen ($SG) was not linked to the cyclospora outbreak - are you a buyer of the stock?

129 votes

NFLX

Netflix ($NFLX) is down sharply following Q2 earnings, hitting a fresh 52-week low. Are you buying the dip?

3.9K votes

Info

CategoriesBase Ecosystem, +1 more

About

This project will design a new RNA therapeutic that nudges the longevity-linked FOXO3 gene into its health-promoting form to halt the tissue breakdown behind degenerative disc disease—opening a precise, scalable route to drugs that extend healthspan. Dr. Lorna Harries’ lab has identified an innovative way to modulate FOXO3, a well known and yet undrugged longevity target, and propose leveraging it to address chronic lower back pain stemming from degenerative disc disease. They plan to make short, lab-made modified RNA molecules (antisense oligonucleotides) that selectively switch FOXO3’s “good” message on, first in human cells and mini-disc models. Success would yield 1) a lead drug candidate, 2) proof it can restore disc health, and 3) the data needed for patenting and further development. The same molecules could later be adapted to treat many other age-related conditions, helping people stay healthy for longer.

Advertisement|Remove ads.